<DOC>
	<DOCNO>NCT00311896</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety subcutaneous administration 45 day Bemiparin ( 3,500 UI/day ) cancer patient CVC , prevent CVC-related deep venous thrombosis ( CVC-DVT )</brief_summary>
	<brief_title>Efficacy &amp; Safety Prophylaxis With Bemiparin Cancer Patients With Central Venous Catheter ( BECAT )</brief_title>
	<detailed_description>Venous thromboembolism ( VTE ) common complication patient cancer principally association central vein catheter ( CVC ) . The clinical benefit antithrombotic prophylaxis CVC-related VTE cancer patient remain unclear.The aim study evaluate efficacy safety administration Bemiparin cancer patient central venous catheter ( CVC ) . This study design multicenter , randomize , double-blind , placebo-controlled study . On day CVC insertion , eligible patient randomly assign receive subcutaneously either bemiparin ( 3,500 UI/day ) placebo use preloaded syrinx 45 day . The primary efficacy endpoint combine incidence double blind treatment period Clinical symptomatic CVC-DVT verify objectively ( Doppler ultrasonography phlebography ) subclinical asymptomatic CVC-DVT confirm elective bilateral Doppler ultrasonography perform 45Â±5 day randomization .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Patients 18 year old either sex give informed consent participate study . Patients neoplastic process , CVC administration antitumoral treatment treatment related neoplastic process . Patients platelet count 30,000/mm3 . Patients hemorrhagic symptomatology time inclusion Patients history clinically evident hemorrhagic episode and/or increase bleeding due homeostatic alteration contraindicates anticoagulant treatment and/or past two month present least one following : active hemorrhage organic lesion susceptible bleeding ( e.g . active peptic ulcer , hemorrhagic cerebrovascular accident , aneurysms ) . Major surgery past two month . Known hypersensitivity LMWH , heparin substance porcine origin . Patients congenital acquire bleeding diathesis . Damage surgical intervention central nervous system , eye ear within past 6 month . Acute bacterial endocarditis slow endocarditis . Patients history heparinassociated thrombocytopenia . Patients severe renal failure ( serum creatinine 2 mg/dl ) hepatic insufficiency ( value AST and/or ALT &gt; 5 time normal value establish reference range local hospital laboratory ) . Severe arterial hypertension ( systolic blood pressure 200 mmHg and/or diastolic blood pressure 120 mmHg ) . Patients suspect inability/or inability comply treatment and/or complete study . Patients participate another clinical trial do past 30 day . Patients life expectancy le 3 month . Women pregnant breastfeeding , possibility become pregnant study . Patients treatment anticoagulant treatment week previous insert CVC ( include prophylaxis heparin hepatic venoocclusive disease ) . Patients diagnose acute leukemia await transplant hematopoietic progenitor 90 day study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Thrombosis</keyword>
	<keyword>Catheter</keyword>
	<keyword>Bemiparin</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>